ICD-10 code R84.4: Abnormal immunological findings in respiratory specimens

Key takeaways

ICD-10 code R84.4 reports an abnormal immunological finding in a specimen taken from the respiratory organs or thorax.

Culture and organism growth results belong to R84.5. The laboratory method decides which of the two codes applies.

The R84 specimen list covers bronchial washings, nasal secretions, pleural fluid, sputum, and throat scrapings.

An immunology result run on blood or serum falls outside R84 entirely. A raised antibody titer in serum is coded R76.0.

Practice management software like Pabau keeps the laboratory report, the provider note, and the diagnosis code in one patient record.

ICD-10 code R84.4 reports an abnormal immunological finding in a specimen taken from the respiratory organs or thorax. One word in that descriptor does all the work, and the word is immunological.

That word is also what separates R84.4 from R84.5, which sits one digit away. R84.5 belongs to culture and organism growth. R84.4 belongs to the immunoassay run on the same specimen.

The method decides something bigger too. It decides whether the finding belongs in R84 at all, because an immunology panel drawn from serum is classified somewhere else. Both boundaries are worth getting right the first time.

R84.4 is billable and complete at four characters

R84.4 is a billable ICD-10-CM code. It takes no fifth character, so nothing gets added to it. The code is valid on claims for FY2026, and that version took effect on October 1, 2025.

Its full descriptor reads Abnormal immunological findings in specimens from respiratory organs and thorax. Confirm that wording against the CDC/NCHS ICD-10-CM browser each fiscal year. Descriptors and code validity are reviewed annually.

The Includes note on R84 lists every qualifying specimen

R84.4 covers bronchial washings, nasal secretions, pleural fluid, sputum, and throat scrapings. The tabular list attaches that Includes note to category R84, not to each subcode. It still applies to R84.4 in full.

• Bronchial washings. Coders generally read this to cover bronchoalveolar lavage fluid collected at bronchoscopy.
• Nasal secretions. Fluid collected from the nasal cavity rather than the nasopharynx.
• Pleural fluid. Collected by thoracentesis or drawn from an existing chest drain.
• Sputum. Expectorated or induced, and sent for a laboratory assay rather than gross inspection.
• Throat scrapings. Material taken from the pharyngeal surface.

Two edge cases come up constantly. The first is an Excludes1 note at the category level: blood-stained sputum is reported with R04.2, whatever the laboratory later runs on that specimen.

Then comes the specimen the note never mentions. Tracheal aspirates and nasopharyngeal swabs are not named, yet neither is excluded and both come from respiratory organs. Assignment then rests on how the provider describes the specimen.

Every R84 subcode names a different kind of test result

All ten subcodes in R84 describe the same specimens. What separates them is the type of laboratory finding reported. Picking the wrong one is the most common error on these claims, and it usually comes down to R84.4 against R84.5.

R84.9 exists for records that never say which test produced the abnormal result. Reach for it only when the report genuinely does not specify. An unspecified code invites a documentation request.

R84.4 covers immunology, R84.5 covers culture

Three questions settle almost every case at the R84.4 boundary.

• What does the tabular list say? R84.5 carries the inclusion term Positive culture findings, which ties it to organism growth. R84.4 carries no inclusion term at all.
• What does the alphabetic index say? Under Abnormal, specimen, respiratory organs, the subterm immunology routes to R84.4. The subterm microbiology routes to R84.5.
• Does the organism matter? No. The method used on the specimen picks the code, whatever the result happens to name.

R84.5 also carries an Excludes1 note against colonization status, Z22.-. A patient documented as colonized rather than infected takes the Z22 code, and R84.5 comes off the claim. No equivalent note applies to R84.4.

Nothing bars reporting both, though. The category carries no Excludes note between its own subcodes. One bronchial washing can therefore support both codes, as long as the record documents each result separately.

Serum and blood results never belong in R84.4

Section R83-R89 carries an Excludes2 note against abnormal findings on examination of blood, R70-R79. Immunology run on a serum sample therefore sits outside R84. That holds even when the clinical question is entirely about the lungs.

This is where R84.4 gets misapplied most often. A raised Aspergillus IgG titer drawn from blood is a serum finding, and R76.0 is the code for it. Other blood findings share that same block, including ICD-10 code R78.4.

The same trap shows up outside pulmonology. A rheumatoid arthritis test reports antibody results drawn from blood, so those findings never reach R84 either. Specimen first, method second, and the category follows.

The block repeats one pattern. Where a category is subdivided by test type, the immunological findings land on the subcode ending in 4. Change the specimen and the category changes, while the subcode stays put.

Four assays that put R84.4 on the claim

Immunological testing on a respiratory specimen looks for an antibody, an antigen, or a cell surface marker. The laboratory runs that search in the fluid itself. Four assay families account for most of what reaches a coder.

• Antigen enzyme immunoassay. The laboratory measures Aspergillus galactomannan directly in lavage fluid. An optical density index at or above 1.0 is treated as suggestive of invasive aspergillosis.
• Direct immunofluorescence. Labeled monoclonal antibodies applied to induced sputum or lavage fluid identify Pneumocystis jirovecii under a fluorescence microscope.
• Lymphocyte immunophenotyping. Flow cytometry on lavage fluid returns a CD4 to CD8 ratio. That ratio often runs high in sarcoidosis and low in hypersensitivity pneumonitis.
• Flow cytometry on pleural fluid. An antibody panel can flag a monotypic B-cell population or an aberrant T-cell phenotype in an effusion.

None of these results is a diagnosis on its own. The lavage CD4 to CD8 ratio in biopsy-proven sarcoidosis has been reported anywhere from 0.5 to 37.3. That number supports a workup rather than closing one, and it is the situation R84.4 was written for.

When R84.4 belongs on the claim

Chapter 18 codes are acceptable for reporting when a related definitive diagnosis has not been established by the provider. That is guideline I.C.18.a in the FY2026 ICD-10-CM Official Guidelines, and it is the whole test for R84.4.

Two settings apply that test differently, and mixing them up produces most of the denials on these claims.

Outpatient claims can carry an open finding

Section IV tells outpatient coders not to report probable, suspected, questionable, rule out, or working diagnoses. Code to the highest degree of certainty for that visit instead, which expressly includes abnormal test results.

There is a limit, though. When a diagnostic test has been interpreted by a physician and the final report is available at coding, report the confirmed diagnosis from that interpretation. Related signs and symptoms are not added alongside it.

So R84.4 fits an outpatient encounter where the immunology result is abnormal and the interpretation stops short of a diagnosis. Reviewing a lavage galactomannan index with treatment still undecided is the standard case. Plenty of practices now run that review through telemedicine software, and the setting changes nothing about the code.

Inpatient claims need a provider’s comment first

The inpatient rule runs the other way. Section III.B says abnormal laboratory findings are not coded on an inpatient record unless the provider indicates their clinical significance.

An abnormal galactomannan index sitting in the chart is not enough on its own. If the result is outside the normal range and the provider ordered further tests or started treatment, query the provider before adding R84.4.

R84.4 also needs a present on admission indicator. No R code appears on the CMS FY2026 POA exempt list, so that field has to be completed on inpatient claims which report POA.

One further guideline shapes sequencing in both settings. A sign or symptom routinely associated with a documented diagnosis is not reported as an additional code. Once invasive pulmonary aspergillosis is confirmed, the abnormal galactomannan result is part of that diagnosis.

How an R84.4 claim actually moves

R84.4 never bills on its own. In medical billing terms it justifies a service rather than describing one, so it rides on the encounter or the laboratory work that produced it.

1. The specimen reaches the laboratory. Collection gets documented in the note, with the site and the method named.
2. The report comes back abnormal. Its method line is what later picks R84.4 over R84.5.
3. The provider reads it. Their interpretation either names a diagnosis or leaves the finding open.
4. The coder assigns the code. R84.4 goes in the diagnosis field, alongside anything else the visit supports.
5. The service line points to it. A diagnosis pointer ties each billed service to the diagnosis that justifies it.

Two things derail that sequence. The report reaches billing without the provider’s reading attached, or the diagnosis lands after the claim has already gone out. Either way, the code on the claim stops matching the record.

What the record must show before you submit

Most R84.4 denials trace back to a thin record rather than a misread rule. Five elements carry the code, and a reviewer looks for all five.

1. Specimen type and collection method. Bronchoalveolar lavage fluid obtained at bronchoscopy tells a reviewer far more than a reference to lab results.
2. The assay that was run. Name the method, whether that is galactomannan enzyme immunoassay, direct immunofluorescence, or flow cytometry immunophenotyping.
3. The result and why it reads as abnormal. A numeric index, a ratio, or a described pattern carries more weight than the word positive.
4. The provider’s reading of the finding. On an inpatient record this is mandatory, because Section III.B requires a statement of clinical significance.
5. The absence of a confirmed diagnosis. If the note lands on a diagnosis, that code replaces R84.4, and the record should show when the change happened.

Structured fields make this easier to hold together. Digital forms capture the specimen and the assay at the point of care. That beats leaving both in free text for a coder to reconstruct later. Nursing records help too, since an impaired gas exchange care plan usually logs the collection and the patient’s respiratory status around it.

Test-heavy specialties feel this hardest. A practice running functional medicine software may order dozens of panels a week, and every abnormal result still needs those same five elements behind it.

Where these claims usually go wrong

Five errors account for most of the rework on R84.4. Each one is easy to catch in a pre-submission check.

• Coding a positive culture as R84.4. Growth belongs to R84.5, and the two codes sit one digit apart.
• Coding a serum antibody titer as R84.4. Serum findings sit in R70-R79, and R76.0 covers a raised titer.
• Reaching for R84.9 when the report names the method. Unspecified codes draw documentation requests that a specific code avoids.
• Leaving R84.4 on the claim after the diagnosis is confirmed. The confirmed code replaces it from that point forward.
• Reporting R84.4 on an inpatient record with no provider comment. Section III.B needs a statement of clinical significance first.

Building these checks into EHR integration catches them earlier than a payer will. A rule that fires while the coder is still in the chart costs minutes, and a denial costs weeks.

How Pabau keeps the laboratory result and the code together

Coding errors on findings like this one happen in the handover. A provider reads the immunology report and forms a view. Someone in billing turns that view into a code, often without the report in front of them.

Practice management software like Pabau holds the laboratory report, the provider note, and the diagnosis code in one patient record. Pabau’s claims management software then checks the fields an insurer requires, and it holds the claim until they are complete.

A status dashboard shows whether each claim is pending, submitted, processing, paid, or in error. Clinical documentation tools capture the specimen, the assay, and the provider’s reading in structured fields. Outside laboratory results stay tied to the encounter that prompted them.

So when a payer asks why R84.4 was reported rather than a confirmed diagnosis, answering it becomes a search instead of an afternoon.

Keep the lab result and the code in one record

Pabau holds the immunology report, the provider note, and the diagnosis code in one patient record. Every claim is checked for the fields insurers require before it goes out.

Book a demo

Conclusion

R84.4 earns its place on a claim under two conditions. First, the specimen has to come from the respiratory organs or thorax. Second, the abnormal result has to come from an immunological assay run on it.

Read it that way and the code stops competing with R84.5, which belongs to culture, and with R76, which belongs to serum. Those two boundaries account for most of the misassignments in the category.

The setting then decides the rest. Outpatient claims can carry the finding while the diagnosis is open, and inpatient claims need the provider to say the finding matters. Book a demo to see how Pabau keeps the lab report, the note, and the code on one screen.

Continue your research

Coding another abnormal finding without a diagnosis? ICD-10 code O28.2 shows how the same finding-first logic works in a different chapter.

Documenting how a result was interpreted? Medical decision making explains what a note has to show for the reasoning behind a diagnosis to hold up.

Tightening up how specimens get recorded? Nursing documentation covers the collection detail that reviewers look for after the fact.

Building structured clinical forms? Medical forms at your healthcare practice covers capturing specimen and result detail in fields rather than free text.

Writing up a follow-up on an open result? DAR notes gives you a format that keeps the finding, the action, and the response together.

Frequently asked questions